SELLAS Life Sciences has reported positive results from a pivotal Phase 3 trial of its experimental cancer vaccine for acute myeloid leukaemia (AML), with patients given the vaccine living a median of nine months longer than those on the best available treatment.
The trial, known as REGAL, tested galinpepimut-S (GPS) as a maintenance therapy in 126 patients who had reached a second or later remission after salvage treatment and who could not undergo a stem cell transplant, a group with very few remaining options. Patients were randomised equally between GPS alone and the investigator’s choice of best available treatment, which included observation, a hypomethylating agent, venetoclax or low-dose cytarabine.
The study met its primary endpoint of overall survival. Patients receiving GPS lived a median of 24.0 months, compared with 14.7 months for those on best available treatment, a 41% reduction in the risk of death, with a hazard ratio of 0.59 and a two-sided p-value of 0.035. The analysis was carried out once 80 deaths had occurred, as specified in advance in the trial’s statistical plan.
GPS is designed to train the immune system to attack cancer cells carrying the WT1 protein, which is found in a wide range of blood cancers and solid tumours. The vaccine, licensed from Memorial Sloan Kettering Cancer Center, consists of four WT1-derived peptides intended to trigger both CD4+ and CD8+ T-cell responses against residual leukaemia cells.
The treatment was generally well tolerated, SELLAS said, with a safety profile in line with earlier studies and no new safety signals. Treatment-related side effects were mostly mild to moderate, most commonly reactions at the injection site.
SELLAS said it plans to meet the US Food and Drug Administration to discuss an accelerated filing strategy and is preparing a Biologics License Application for GPS in the first half of 2027. Detailed results from the trial, including secondary endpoints such as leukaemia-free survival, are still being analysed and will be presented at a major medical conference and submitted for publication in a peer-reviewed journal.
The results are topline data announced by the company and have not yet been peer reviewed, and the FDA has not agreed to any filing route. SELLAS shares rose sharply in premarket trading on Tuesday after the announcement.
Sources: SELLAS Life Sciences press release via GlobeNewswire (https://usanewshour.com/sellas-life-sciences-announces-positive-pivotal-phase-3-regal-trial-data-showing-immunotherapeutic-cancer-vaccine-galinpepimut-s-gps-demonstrated-a-statistically-significant-and-clinically-meaning/432563/) and Fierce Biotech (https://www.fiercebiotech.com/biotech/sellas-marks-nine-month-survival-benefit-late-stage-leukemia-vaccine-study)
